Doustna tabletka antykoncepcyjna – etynyloestradiol i drospirenon – schemat 24+4. Opis przypadku Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2015
Słowa kluczowe:
doustna tabletka antykoncepcyjna, etynyloestradiol, drospirenon
##plugins.themes.bootstrap3.article.main##
Abstrakt
W dzisiejszych czasach ponad 99% aktywnych seksualnie kobiet w wieku reprodukcyjnym stosowało co najmniej jedną metodę antykoncepcyjną. Wybór metody zależy od wielu różnych czynników, w tym wieku, częstości odbywania stosunków seksualnych, liczby partnerów seksualnych, efektywności, akceptacji metody oraz indywidualnych czynników ryzyka.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Błażejewska, A. (2015). Doustna tabletka antykoncepcyjna – etynyloestradiol i drospirenon – schemat 24+4. Opis przypadku . Medycyna Faktów , 8(4(29), 61-63. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2284
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Mansour D., Inki P., Gemzell-Danielsson K.: Efficacy of contraceptive methods: A review of the literature. Eur. J. Contracept. Reprod. Health Care 2010; 15: 4-16.
2. Borgelt-Hansen L.: Oral contraceptives: an update on health benefits and risks. J. Am. Pharm. Assoc. (Wash) 2001; 41(6): 875-886.
3. World Health Organization. Contraception in adolescence. WHO Library Cataloguing in Publication Data, Geneva 2004.
4. US Food and Drug Administration (FDA). FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone [online].
5. Food and Drug Administration. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Silver Spring (MD): FDA; 2011.
6. Burkman R., Schlesselman J.J., Zieman M.: Safety concerns and health benefits associated with oral contraception. Am. J. Obstet. Gynecol. 2004; 190(4 supl.): S5-22.
7. Klipping C., Duijkers I., Trummer D., Marr J.: Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78: 16-25.
8. American College of Obstetricians and Gynecologists. ACOG Committee on Practice Bulletins-Gynecology. Premenstrual syndrome: Clinical management guidelines for obstetrician-gynecologists. ACOG Pract. Bull. 2000; 15: 448-455.
9. Royal College of Obstetricians and Gynaecologists Guideline No. 48. Management of premenstrual syndrome.
10. Clayton A.H.: Symptoms related to the menstrual cycle: diagnosis, prevalence, and treatment. J. Psychiatr. Pract. 2008; 14(1): 13-21.
2. Borgelt-Hansen L.: Oral contraceptives: an update on health benefits and risks. J. Am. Pharm. Assoc. (Wash) 2001; 41(6): 875-886.
3. World Health Organization. Contraception in adolescence. WHO Library Cataloguing in Publication Data, Geneva 2004.
4. US Food and Drug Administration (FDA). FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone [online].
5. Food and Drug Administration. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Silver Spring (MD): FDA; 2011.
6. Burkman R., Schlesselman J.J., Zieman M.: Safety concerns and health benefits associated with oral contraception. Am. J. Obstet. Gynecol. 2004; 190(4 supl.): S5-22.
7. Klipping C., Duijkers I., Trummer D., Marr J.: Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78: 16-25.
8. American College of Obstetricians and Gynecologists. ACOG Committee on Practice Bulletins-Gynecology. Premenstrual syndrome: Clinical management guidelines for obstetrician-gynecologists. ACOG Pract. Bull. 2000; 15: 448-455.
9. Royal College of Obstetricians and Gynaecologists Guideline No. 48. Management of premenstrual syndrome.
10. Clayton A.H.: Symptoms related to the menstrual cycle: diagnosis, prevalence, and treatment. J. Psychiatr. Pract. 2008; 14(1): 13-21.